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Abstract Communication about palliative treatment options
requires a balance between providing patients with sufficient
information and not providing unwanted information. Surveys
have indicated that many patients with advanced cancer ex-
press a wish to receive detailed information. In this prospec-
tive multicenter study, the information desire of patients with
advanced breast or colorectal cancer was further investigated
by offering treatment-related information to patients using a
decision aid (DA). In addition, this study explored oncolo-
gists’ awareness of their patients’ information desire.
Seventy-seven patients with advanced breast or colorectal
cancer facing the decision whether to start second-line pallia-
tive chemotherapy were offered a DA by a nurse. This DA
contained information on adverse events, tumor response, and
survival. The nurse asked the patient whether each informa-
tion item was desired. Ninety-five percent of patients chose to
receive information on adverse events, 91 % chose to receive
information on tumor response, and 74 % chose to receive
information on survival. Oncologists’ judgment of patients’
information desire was 100, 97, and 81 %, respectively. For
all three information items together, oncologists correctly
judged the information desire of 62 % of patients. This study
confirms that many patients with advanced cancer wish to
receive detailed information on the benefits and risks of palli-
ative treatment options when the information is actually avail-
able. Oncologists were adequately aware of this high informa-
tion desire, but had some difficulty judging the information
desire of individual patients. A stepped approach to giving
information (Bpreview, ask, tell, ask^) may help to better meet
patients’ information needs.
Keywords Breast cancer . Colorectal cancer . Palliative
chemotherapy . Information preference . Decision aids
Introduction
Palliative chemotherapy aims at prevention and relief of dis-
ease symptoms. The impact of treatment on length of life is
often modest or uncertain, and the occurrence of adverse
events can negatively impact quality of life. Therefore, the
decision whether to start palliative chemotherapy involves a
personal trade-off between the potential benefits and risks of
treatment [1]. When informing patients about this treatment
option, information provision needs to be balanced in order to
meet informed consent, while not providing any unwanted
information [2].
In daily clinical practice, achieving this balance may be
difficult. Findings from surveys suggest that many patients
in the palliative treatment setting wish to receive detailed
treatment-related information [3, 4]. Little is known about
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the ability of physicians to judge patients’ information desire.
One study in the palliative setting showed that physicians had
difficulty predicting patients’ stated preferences for informa-
tion on expected survival [5]. Likewise, studies on treatment
decision-making showed poor concordance between patients’
preferences and physicians’ perceptions of these preferences
[5–9]. Reference has been made to the Bsilent misdiagnosis^
of patients’ treatment preferences [10].
The present study focused on the treatment decision wheth-
er or not to start second-line palliative chemotherapy. Beyond
first-line treatment for advanced disease, benefits of subse-
quent lines of chemotherapy are reduced and also often less
clear, emphasizing the preference-sensitive nature of this de-
cision. Furthermore, the study focused on two common types
of cancer, i.e., colorectal and breast cancer. Unlike previous
studies using hypothetical scenarios, patients’ information de-
sire was assessed by actually offering information about the
benefits and risks of treatment options to patients, using a
decision aid (DA). The aim of the study was to investigate
patients’ desire for information about the benefits and risks of
second-line treatment, and explore their oncologists’ aware-
ness of this desire.
Methods
Study Design
The study described here was part of a multicenter random-
ized trial; this trial was registered in the Netherlands Trial
Registry (NTR1113), and details have been published in the
study protocol [11]. In short, the target population consisted of
patients with advanced breast or colorectal cancer facing the
treatment decision whether or not to start second-line pallia-
tive chemotherapy. To identify these patients, we recruited
patients who had started or were starting first-line palliative
chemotherapy for advanced breast or colorectal cancer.
Exclusion criteria were labile personality structure (as
assessed by the physician), a Karnofsky performance score
lower than 60, and insufficient knowledge of the Dutch lan-
guage. The study was approved by the regional ethics review
committee (CMO Arnhem-Nijmegen) and the research ethics
committees of all participating centers.
The medical oncologist or nurse assessed the potential el-
igibility of consecutive patients. Health professionals were
instructed to introduce the study topic as to Bhow to involve
the opinion of patients in their treatment.^ Patients were not to
be told that detailed risk information (e.g., on survival) could
be provided in this study, to avoid selection of patients based
on information desire. Health professionals asked patients for
permission to be approached by the researcher, who obtained
written informed consent.
After inclusion, patients were monitored for disease pro-
gression and the subsequent decision whether or not to start
second-line palliative chemotherapy. Patients who were pro-
posed second-line treatment were randomly assigned to re-
ceive (1) the usual treatment-related information from the on-
cologist (control group) or (2) the usual treatment-related in-
formation from the oncologist plus a DA with information
from a nurse (intervention group) in a 1:2 ratio. Treatment
allocation was concealed using sealed envelopes which were
opened by the nurse after the oncologist mentioned disease
progression and offered second-line treatment. Unequal ran-
domization was employed because the control group was only
needed to evaluate the DAs (results of the randomized com-
parison are reported in a separate manuscript), while data from
the intervention group were also used to address questions on
patients’ information desire [11].
Outcome Measures
For each patient included in the study, the oncologist complet-
ed an inclusion form with patient and disease characteristics,
and stated a judgment of whether the patient would desire
information for each of the three items in the DA: (1) adverse
events, (2) tumor response, and (3) survival. Patients complet-
ed a baseline questionnaire on sociodemographic variables.
When disease progression occurred and the oncologist had
proposed second-line chemotherapy, patients in the interven-
tion group received the DA in a subsequent consultation with
a nurse, typically within a week. The data on risks and benefits
presented in the DAwere obtained from systematic reviews of
the literature for the two tumor types [12, 13]. DAs were
developed for 11 chemotherapeutic regimens commonly used
as second-line treatment for patients with advanced breast or
colorectal cancer. All DAs were reviewed and approved by the
participating oncologists. An example of a DA for colorectal
cancer is available in an online supplement.
Patients’ information desire was obtained as follows. Using
the DA, information on the three items was presented in a
stepwise fashion (see the online supplement). The nurse first
explained the type of information that could be expected and
then asked the patient whether the information item was de-
sired or not. If desired, the information was provided. The
nurse asked the patient for each item whether any information
on that item had been provided by the oncologist, to explore
whether patients’ information desire was associated with the
perception of previously having received information on these
items from the oncologist.
Statistical Analysis
Descriptive statistics were used to summarize patients’ infor-
mation desire and oncologists’ judgment. Concordance be-
tween these two outcome measures for each of the three
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information items was examined by calculating the percentage
of overall concordance, positive agreement (concordance for
wanting the information), and negative agreement (concor-
dance for not wanting the information), as has been suggested
by Cicchetti and Feinstein [14]. To obtain more insights in the
number of patients whose information desire for all three of
the items was correctly judged by their oncologist, we calcu-
lated concordance for all three information items on the level
of the individual patient. Associations between patients’ infor-
mation desire and perceptions of having previously re-
ceived information from the oncologist were explored
using chi-square tests. All analyses were performed using
SPSS version 20.
Results
Participating Patients and Oncologists
Patient flow is depicted in Fig. 1. Out of 441 patients assessed
for potential eligibility, 55 (12 %) did not meet the inclusion
criteria, 31 (7 %) were excluded, and 34 (8 %) were not
approached by the oncologist, and therefore, the inclusion
criteria could not be verified. Of the 321 patients approached
to participate in this study, 263 (82 %) gave informed
consent. From this group, 92 patients (35 %) were not
faced with the decision on second-line chemotherapy
and therefore did not belong to the target population
of this study. Another 43 patients (16 %) faced the
treatment decision but were not randomized and
dropped out of the study. Of the 128 patients who were
randomized, 83 patients were randomized to the intervention
group, and 77 (93 %) completed the intervention interview
with the nurse using the DA. Oncologists’ judgment of infor-
mation desire was available for 74 of these patients. Table 1
lists the characteristics of these 74 patients and the 40 partic-
ipating oncologists from 17 hospitals.
Information on Adverse Events, Tumor Response,
and Survival
During the interview, 95 % of patients chose to receive infor-
mation on adverse events, 91 % chose to receive information
on tumor response, and 74 % chose to receive information on
Recruitment of patients who started first-line palliative chemotherapy 
Consultation with oncologist during first-line chemotherapy 
Assessed for potential eligibility (n=441) 
Not included in the study (n=178) 
• Did not meet inclusion criteria (n=55) 
• Labile personality structure (n=12) 
• Karnofsky score lower than 60 (n=14) 
• Insufficient Dutch language proficiency (n=5) 
• Other reasons (e.g. patient not asked in time) (n=34) 
• Declined to participate (n=58) 
Excluded (n=135) 
• Not faced with the decision on second-line chemotherapy (n=92) 
- No disease progression within the follow-up of the study (n=40)            
- Bad medical condition or died (n=47)              
- Already decided not to want any further chemotherapy (n=5)    
• Not randomized (n=43) 
- Missed at disease progression (n=35)   
- Refused further participation in study (n=6)  
- Other reasons (e.g. went to another hospital) (n=2)  
Included in the study and monitored for disease progression (n=263) 
Consultation with oncologist about second-line chemotherapy 
Randomized (n=128) 
Allocated to receive usual care plus the decision aid (n=83) 
• Received the decision aid (n=77) 
• Did not receive the decision aid (n=6) 
- No time before start of chemotherapy (n=2) 
- Refusal patient (n=4) 
Allocated to receive usual care (n=45)
Fig. 1 Patient flow chart
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survival. There were no differences in information desire be-
tween patients who perceived or did not perceive to have
received any information on this topic from the oncologist.
Oncologists thought that of 74 patients, all would want infor-
mation on adverse events (100 %), 97 % would want infor-
mation on tumor response, and 81 % would want information
on survival.
Concordance Between Oncologists’ Judgment
and Patients’ Information Desire
Table 2 shows the concordance between oncologists’ judg-
ment and patients’ information desire. Depending on the item,
oncologists correctly judged the information desire of 47 to 70
out of 74 patients (64–95 %). Positive agreement for wanting
to see information on adverse events and tumor response was
97 and 94 %, respectively, and 77 % for wanting to see infor-
mation on survival. Negative agreement for not wanting to see
information on the three items ranged between 0 and 18%.On
the level of the individual patient, oncologists’ judgments
were concordant with the information desire of 46 patients
(62 %) for all three information items.
Discussion
This study sought to determine whether the high information
desire as stated by patients with advanced cancer in surveys
would also hold true when actually offering treatment-related
information in a DA. The findings confirm that almost all
patients with advanced breast or colorectal cancer wished to
receive information on adverse events and tumor response
rates, and that three quarters of patients wished to receive
detailed survival information related to second-line treatment
options.
The oncologists in this study were adequately aware of
their patients’ high information desire. They were generally
capable of identifying patients wanting information about ad-
verse events and tumor response, but had more difficulty iden-
tifying patients wanting information about survival and pa-
tients not wanting the available information. These results
are in line with the previously described Bsilent misdiagnosis^
of patients’ information preferences [5], and treatment and
participation preferences [5–10].
The majority of patients in this study wished to receive all
available information from the DA, including detailed surviv-
al information. However, audio-recordings of consultations on
first-line palliative chemotherapy have shown that 61 % of
patients are not given survival information [15]. In addition,
a systematic review illustrated that communication on prog-
nosis is characterized by lack of clarity, lack of an estimate of
expected survival, and avoidance of this topic by focusing on
active treatment options [16]. Perhaps not surprisingly, studies
have shown that more than two thirds of patients who had
started first-line palliative chemotherapy did not seem to un-
derstand that the goal of treatment was not cure [17], and that
only 49 % of patients with advanced cancer were fully aware
of their prognosis [4]. Oncologists might be hesitant to impart
survival information, possibly fearing a negative impact on
the patient [18]. Such fear, however, may not be warranted.
For instance, in patients with advanced cancer, full prognostic
discussion was associated with lower levels of depression and
did not impact on anxiety [19]. In the same vein, prognostic
information could be provided to patients without taking away
hope [20], and end-of-life discussions did not inflict psycho-
logical distress [21]. On the contrary, not discussing prognosis
may cause distress and may preclude patients from
reorganizing and adapting their lives [22]. It was also found
that patients reporting not having had end-of-life discussions
received more aggressive medical care near death and later
hospice referral, resulting in worse quality of life [21].
What can be done to help clinicians to better meet patients’
desire for information? Our suggested approach for clinicians
is to start discussions by eliciting the patient’s information
desire by using open-ended questions [23]. In addition, a
stepped approach to giving information, as employed in this
study, could help to clarify a patient’s information desire. This
approach includes three steps: (1) giving the patient a preview
of the type of information available, (2) asking whether the
information is desired, and (3) then following the patient’s
desire. This stepwise approach is consistent with recommen-
dations on the communication of prognosis to patients with
advanced disease [23]. DAs can help to implement this ap-
proach by providing numerical estimates of benefits and risks
of treatment options; previous studies showed that DAs can
Table 1 Patient and oncologist characteristics
Patient characteristics (n=74)
Male sex, n (%) 29 (39 %)
Age, median (range) 62 (32–80)
Living with partner, n (%) 57 (77 %)
Employeda, n (%) 20 (40 %)
College education or more, n (%) 21 (28 %)
Colorectal cancer (vs. breast cancer), n (%) 57 (77 %)
Information preference, mean (SD)b 8.6 (1.6)
Oncologist characteristics (n=40)
Male sex, n (%) 18 (45 %)
Academic hospital (vs. peripheral), n (%) 13 (33 %)
Number of judgments made per oncologist, mean (range) 2 (1–8)
SD standard deviation
a Selection of patients <65 years of age, retirement age in the Netherlands
in 2012
b Rating scale from 0 (I want to know nothing about the illness and its
treatment) to 10 (I want to know everything there is to know about the
illness and its treatment)
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improve understanding [24]. The clinician can further pro-
mote understanding by asking what the patient understands
and feels about the information provided [25].
Methodological strengths of our study are that information
desire was assessed by providing treatment-related informa-
tion to patients at the point of decision-making.
Generalizability is facilitated by the recruitment of patients
using broad inclusion criteria, before the moment of disease
progression. To prevent selective patient participation, physi-
cians were instructed to recruit consecutive patients and not to
mention that detailed risk information could be provided. This
study has a number of limitations. Ideally, oncologists’ judg-
ment of their patients’ information desire would be recorded
between the diagnosis of disease progression and the treat-
ment discussion with the patient. However, recording oncolo-
gists’ judgment in this narrow window of opportunity was
expected to result in a large amount of missing data. Asking
oncologists for a retrospective judgment, as was done in a
previous study on palliative treatment decisions [5], would
introduce the risk of recall bias.We therefore decided to record
the oncologists’ judgment beforehand (median time of
5 months before the treatment discussion), knowing that most
oncologists in this study had a long-standing relationship with
their patients (as an indication, median time since first diag-
nosis of disease and diagnosis of metastatic disease were 23
and 10 months, respectively). While our findings are in line
with those of previous studies, they will need to be confirmed
by further studies of real-world treatment decisions. It is also
worth noting that the accuracy of predicting patient’s desire
for survival information may vary between doctors, but this
could not be analyzed due to the small number of judgments
made per doctor. In hindsight, it would have been worthwhile
to also ask the patients in the control arm of the randomized
trial about their information desire, without offering the infor-
mation, to examine the extent to which patients’ information
desire is dependent on the context in which it is assessed.
In conclusion, this study confirms that many patients with
advanced cancer wish to receive detailed information on the
benefits and risks of palliative treatment options. Oncologists
were aware of this high information desire, but had some
difficulty judging the information desire of individual patients.
A stepped approach, possibly facilitated by the use of DAs,
may help to better meet patients’ information needs.
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